ELITE PHARMACEUTICALS INC /NV/ Gross Profit

Quick Answer

ELITE PHARMACEUTICALS INC /NV/ reported Gross Profit of $40.09 million for fiscal year 2025.

ELITE PHARMACEUTICALS INC /NV/ Gross Profit — Annual History

Fiscal Year Gross Profit YoY Change
2025 $40.09M +52.1%
2024 $26.36M +58.8%
2023 $16.59M +12.2%
2022 $14.80M +24.7%
2021 $11.87M +48.7%
2020 $7.98M +178.2%
2019 $2.87M -27.4%
2018 $3.95M +5.6%
2017 $3.74M -53.3%
2016 $8.01M +300.4%
2015 $2.00M +46.6%
2014 $1.37M +25.4%
2013 $1.09M -22.8%
2012 $1.41M -11.3%
2011 $1.59M

Quarterly Gross Profit

Quarter Ending Gross Profit YoY QoQ
December 31, 2025 $12.95M +111.7% -8.0%
September 30, 2025 $14.07M +71.7% -48.3%
June 30, 2025 $27.23M +221.3% +344.9%
December 31, 2024 $6.12M -13.1% -25.4%
September 30, 2024 $8.20M +27.1% -3.3%
June 30, 2024 $8.47M +78.4% +20.4%
December 31, 2023 $7.04M +43.1% +9.2%
September 30, 2023 $6.45M +68.6% +35.7%
  • ELITE PHARMACEUTICALS INC /NV/ showed an increase of +52.1% in Gross Profit compared to the prior fiscal year.
  • Over the 2011–2025 period, ELITE PHARMACEUTICALS INC /NV/’s gross profit has grown by 2419.8% (from $1.59 million to $40.09 million).
  • The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment